Table 1 Characteristics of 137 patients treated with sunitinib due to advanced GIST
Clinicopathological features | No of patients (%) | |
|---|---|---|
Total number of patients | 137 (100) | |
Age [years] at the start of therapy with sunitinib | Median (range) | 55 (15-82) |
≤45 | 14 (10) | |
> 45 | 123 (88) | |
Gender | Female | 63 (46) |
Male | 74 (54) | |
Primary tumor site | Stomach | 46 (33.5) |
small bowel | 79 (57.6) | |
large bowel/rectum | 4 (2.9) | |
other or intraperitoneally with unknown primary origin | 8 (5.8) | |
Time on imatinib therapy | ≤ 6 months (early resistance) | 25 (18.2) |
6-12 months | 16 (11.7) | |
> 12 months | 96 (70.1) | |
Primary reason for stop of imatinib therapy | Disease progression | 135 (98.5) |
Imatinib intolerance | 2 (1.5) | |
ECOG Performance Status | 0 | 48 (35) |
1 | 72 (52.6) | |
≥2 | 17 (12.4) | |
Tumor genotype* | Exon 11 KIT mutation | 52 (58.4) |
Exon 9 KIT mutation | 15 (16.9) | |
PDGFRA mutation | 12 (13.5) | |
Wild-type | 10 (11.2) | |
Data not available | 48 |